Alok Goyal, MD
Internal Medicine · Milwaukee, WINPI 1487634036
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 405 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 405 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AstraZeneca$774
- AbbVie$612
- Otsuka America Pharmaceutical, Inc.$430
- Astellas Pharma US Inc$379
- Lilly USA, LLC$347
- plus $4K from 54 others
What the payments were for
- Food & beverage$7,08896%
- Education$3184%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$106
How this compares
$7,407 in reported general payments places this provider in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 895 | $302,945 |
| LinzessLinaclotide | 252 | $137,165 |
| IngrezzaValbenazine Tosylate | 16 | $116,034 |
| TrulicityDulaglutide | 129 | $114,660 |
| JardianceEmpagliflozin | 212 | $88,182 |
| OzempicSemaglutide | 82 | $84,031 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $55,748 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $42,367 |
| JanuviaSitagliptin Phosphate | 74 | $37,691 |
| XareltoRivaroxaban | 101 | $36,983 |
| MyrbetriqMirabegron | 111 | $36,430 |
| TradjentaLinagliptin | 53 | $28,684 |
| ZenpepLipase/Protease/Amylase | 28 | $27,872 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $27,699 |
| EntrestoSacubitril/Valsartan | 75 | $26,724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $231 | $302,945895 claims |
| AbbVieLinzess | $612 | $137,165252 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $347 | $129,893146 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $143 | $128,800289 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $285 | $116,03416 claims |
| Novo NordiskOzempic, Rybelsus | $19 | $110,662109 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $46 | $85,857176 claims |
| GileadBiktarvy | $157 | $55,74813 claims |
| Johnson & JohnsonXarelto | $1,204 | $36,983101 claims |
| Astellas Pharma US IncMyrbetriq | $379 | $36,430111 claims |
| Aimmune Therapeutics, Inc.Zenpep | $51 | $27,87228 claims |
| NovartisEntresto | $118 | $26,72475 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Other internal medicine in Milwaukee
- Jeremiah DeptaMilwaukee$723K
- Erik StilpMilwaukee$116K
- Hammam ShereefMilwaukee$55K
- Muhammad ZamanMilwaukee$37K
- Turgut ZiaMilwaukee$17K
- Mohammad KhanMilwaukee$16K
- Leonard EgedeMilwaukee$12K
- Malik AliMilwaukee$12K
- Mohammed NwilatiMilwaukee$10K
- Champalal GuptaMilwaukee$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.